Abstract Objective. Rituximab (RTX), a B-cell depleting mAb, has been reported to cause
pulmonary toxicity in many patients. As the use of this biologic is increasing, we have …

To review the available published data regarding the incidence, mechanisms of
pathogenesis, clinical presentations and management of pneumonitis caused by anti-cancer …

Background Everolimus-related interstitial lung disease (ILD)(also: pneumonitis) poses a
difficulty for physicians, as it is hard to discriminate ILD from other causes of respiratory …

Interstitial lung disease (ILD) frequently accompanies polymyositis (PM) and
dermatomyositis (DM) and is a major cause of mortality. The rapid diagnosis of ILD is …

The indications for use of B-cell depleting therapy with the monoclonal antibody rituximab
are progressively increasing in patients with renal disease. This includes patients with …

Patients with non-Hodgkin's lymphoma (NHL) receiving rituximab-containing chemotherapy
are at risk of developing respiratory complications, but comprehensive information on these …

Functional imaging by 18 F-fluorodeoxyglucose positron emission tomography (18 F-FDG
PET) is being increasingly incorporated into the evaluation of patients with aggressive non …

Rituximab is a chimeric anti-CD20 monoclonal antibody used to treat CD20+ non-Hodgkin's
lymphoma (NHL). Some pulmonary adverse reactions such as cough, rhinitis …

Overview The respiratory system is particularly susceptible to complications of cancer and
cancer therapy. This vulnerability arises from the stringent architectural requirements for gas …

Drug induced pulmonary toxicity is not uncommon with the use of various chemotherapeutic
agents. Cyclophosphamide is a widely used chemotherapeutic drug in the treatment of …